Prescribing immunosuppressive and comorbidity drugs during conception, pregnancy and breastfeeding - the updated British Society for Rheumatology guideline scope

Clicks: 4
ID: 338725
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #108 of 160 articles by views in Rheumatology Advances in Practice

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 160 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Lay Summary What does this mean for patients? Rheumatic and musculoskeletal diseases are a diverse group of diseases that commonly affect the joints but can affect any organ of the body. These diseases can affect people who are planning pregnancy, are already pregnant or have recently delivered a baby. It is important to control these diseases with medicines because inadequately treated active disease can increase the risk of problems during pregnancy and after the baby is born. People are usually advised to plan pregnancy when their disease is well-controlled and they are taking medicines that are safe to continue during pregnancy. The British Society for Rheumatology published guidance on this topic in 2016 and updated it in 2023. Since then, more information has become available about the safety of medicines used to treat rheumatic diseases in people planning to have a child, as well as during pregnancy and breastfeeding This update will review the latest evidence on drug use in pregnancy. It will also consider people with childhood-onset rheumatic disease. This is important because unplanned pregnancy is common in teenagers, and care needs may be different for people whose disease began in childhood. The guidance will be developed by people with lived experience, as well as specialists in both childhood and adult rheumatic disease.
Reference Key
openalex_W7223519980 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ian Giles, Rachel Allen, Hafsah Amanji, Coziana Ciurtin, Elizabeth Clarke, Maud van de Venne, Hope De Vere, Sarah Dyball, Julia Flint, Margreta Frishman, Mary Gayed, Caroline Gordon, Latika Gupta, Kenneth Hodson, Jonathan Richardson, Victoria Hoskins, Dina Husum, Issrah Jawad, Munther A. Khamashta, Max Lyon, Elizabeth Mabey, Victoria Male, Rebecca McCord, Louise Moore, Christie Parfitt, Helen Richards, Mark Russell, Nadia Sarween, Karen Schreiber, Naz Senvar, Iona Thorne, Sofia Tosounidou, Louise Warburton, David Williams, Chee-Seng Yee, British Society for Rheumatology Guideline Steering Group
Are you one of these authors? Claim your profile
Journal Rheumatology Advances in Practice
Year 2026
DOI
10.1093/rap/rkag140
URL
https://doi.org/10.1093/rap/rkag140
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.